Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?

Table 3 Summary of cohort characteristics and clinical follow up for conventionally fractionated and hypofractionated datasets

Dataset	Total No. pats.	% T1	Histology				% histology unknown	% inoperable	Median age (range) [y]	Median follow-up (range) [m]	Median BED₁₀@isoc (range) [Gy]	Median No. Pats (range)
			% Adeno	% SCC	% NOS	% Other
CF	344	48.0 %	26.3	47.0	15.5	11.2	11.6	86.3	72 (35–90)	28.5 (2–216)	82.0 (67.2-93.5)	43 (31–56)
HF	1975	66.3 %	50.4	31.1	13.5	5.0	35.9	55.2	75 (29–94)	27 (0.3–115)	119.6 (76.8–347.5)	57 (25–177)
Total	2319	63.6 %	45.8	34.1	13.9	6.2	31.9	59.8	74 (29–94)	27 (0.3–216)	105.6 (67.2–347.5)	53 (25–177)

Adeno adenocarcinoma, SCC squamous cell carcinoma, NOS carcinoma not otherwise specified, HF hypofractionated treatment regime, CF conventionally fractionated treatment schedule

ISSN: 1748-717X